CATALYST PHARMACEUTICALS, INC.
CPRXUS売上高
$589M
百万USD
営業利益
$258M
百万USD
純利益
$214M
百万USD
ROE
22.5%
最新FY
EPS
$1.68
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $30M | $8M | $0.07 |
| FY2021 | Q2 | $36M | $12M | $0.11 |
| FY2021 | Q3 | $36M | $10M | $0.10 |
| FY2021 | FY | $141M | $39M | $0.37 |
| FY2022 | Q1 | $43M | $13M | $0.12 |
| FY2022 | Q2 | $53M | $22M | $0.20 |
| FY2022 | Q3 | $57M | $23M | $0.20 |
| FY2022 | FY | $214M | $83M | $0.75 |
| FY2023 | Q1 | $85M | $30M | $0.26 |
| FY2023 | Q2 | $100M | $38M | $0.33 |
| FY2023 | Q3 | $103M | $-31M | $-0.29 |
| FY2023 | FY | $398M | $71M | $0.63 |
| FY2024 | Q1 | $99M | $23M | $0.19 |
| FY2024 | Q2 | $123M | $41M | $0.33 |
| FY2024 | Q3 | $129M | $44M | $0.35 |
| FY2024 | FY | $492M | $164M | $1.31 |
| FY2025 | Q1 | $141M | $57M | $0.45 |
| FY2025 | Q2 | $147M | $52M | $0.41 |
| FY2025 | Q3 | $148M | $53M | $0.42 |
| FY2025 | FY | $589M | $214M | $1.68 |
| FY2026 | Q1 | $149M | $64M | $0.50 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | - | $102M | $119M | $141M | $214M | $398M | $492M | $589M |
| 営業利益 | $-19M | $-19M | $-35M | $32M | $41M | $52M | $102M | $87M | $195M | $258M |
| 純利益 | $-18M | $-18M | $-34M | $32M | $75M | $39M | $83M | $71M | $164M | $214M |
| 総資産 | $42M | $85M | $60M | $112M | $192M | $238M | $376M | $470M | $851M | $1.1B |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $39M | $81M | $51M | $88M | $170M | $207M | $300M | $388M | $728M | $954M |
| 営業CF | - | - | $-26M | $35M | $45M | $60M | $116M | $144M | $240M | $209M |
| EPS | - | - | - | $0.30 | $0.71 | $0.37 | $0.75 | $0.63 | $1.31 | $1.68 |
| BPS | $0.47 | $0.79 | $0.49 | $0.85 | $1.64 | $2.01 | $2.83 | $3.29 | $5.99 | $7.80 |
| ROE | -46.0% | -22.7% | -67.0% | 36.4% | 44.2% | 19.1% | 27.7% | 18.4% | 22.5% | 22.5% |